Implantable system for treprostinil: a real‐world patient experience study. (1st April 2020)

• Record Type: Journal Article
• Authors: Shapiro, Shelley; Bourge, Robert C.; Pozella, Patti; Harris, David F.; Borg, Erick H.; Nelsen, Andrew C.
• Is Part Of: Pulmonary circulation. Volume 10:Number 2(2020)
• Page Start: 1
• Page End: 10
• Publication Date: 2020-04-01
• Subjects: pulmonary arterial hypertension -- quality of life -- physical activity -- prostacyclin -- treprostinil; Pulmonary circulation -- Periodicals; Pulmonary circulation; Electronic journals -- Sciences; Periodicals; 616.24005
• DOI: 10.1177/2045894020907881
• Languages: English
• ISSNs: 2045-8932

Abstract

Abstract : Parenteral prostanoids are effective for improving outcomes in patients with pulmonary arterial hypertension. However, subcutaneous or intravenous delivery via an external pump places a significant burden on patients. Consequently, the Implantable System for Remodulin© (treprostinil) was developed and is associated with a low rate of complications (United Therapeutics (Research Triangle Park, NC) in collaboration with Medtronic, Inc. (Mounds View, MN)). The current real‐world experience study evaluated pulmonary arterial hypertension patients' perceptions of their quality of life, ability to perform activities of daily living, perceptions on the benefits and risks of the implantable system, and their social interactions before and after receiving the implantable system. Pulmonary arterial hypertension patients who had been transitioned from an external infusion pump to the implantable system completed a mix of quantitative and qualitative questions administered online over the course of a six‐day period. A total of 20 patients completed the study. All patients reported that their quality of life, confidence out in public, and ability to travel long distances had improved. Over 90% of patients reported that their overall level of independence was better since receiving the implantable system, and most patients indicated that their ability to independently perform specific activities of daily living had improved. Responses to the qualitative questions suggested that the implantable system saved time, improved interpersonal relationships, and increased freedom. Results from this real‐world patient experience study suggest this novel delivery system provides improvements in factors that are of substantial importance to patients.